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Dear Editor,
We read with much interest the recent observational study of Nougier et al., which aimed at studying 
thrombin generation (TG) and fibrinolysis profiles of COVID-19 patients admitted to an intensive 
care unit (ICU) or to an internal medicine ward and receiving various schemes of prophylactic 
heparin.[1] They reported that thrombin potential remained within normal range despite heparin and 
that fibrinolysis was decreased in relation with increased plasminogen activator inhibitor 1 (PAI-1) 
and thrombin-activatable fibrinolysis inhibitor (TAFI) antigen plasma levels. Using the rotational 
thromboelastometry (ROTEM) delta device with EXTEM reagents and the addition of 0.625µg/mL 
tPA (referred to as ‘TEM-tPA’), they reported decreased clot lysis in COVID-19 patients, which was 
more pronounced in patients who presented a thrombotic event, compared to event-free patients.
This important report provides us the opportunity to raise some crucial methodological issues.
First, a high variability in heparin plasma levels measurements between the available anti-Xa kits has 
been reported, especially for unfractionated heparin (UFH) and for low anti-Xa levels.[2] The authors 
did not specify the kit they used. If they have used a reagent that contains dextran sulfate (as most 
currently available reagents do), this could have led to an overestimation of the heparin levels. Indeed, 
dextran is reported to displace heparin from its binding to plasma proteins other than antithrombin 
(AT), including acute phase reactants, which are increased in COVID-19 patients, and from platelet 
factor 4 (PF4), which can be released by activated platelets.[3] Furthermore, the authors did not 
differentiate in the analysis patients according to the heparin they received (UFH or low molecular 
weight heparins (LMWH)) while they have different effects on laboratory tests (anti-Xa activity, TG 
and ROTEM). Of note, some anti-Xa kits containing exogenous AT can also lead to an 
overestimation of heparin levels in case of AT deficiency, which was infrequent in this series 
though.[3] 
Second, the authors found in vitro TG (calibrated automated thrombogram (CAT), reagent with the 
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administration. Based on this finding, they conclude that the patients presented a major 
hypercoagulability that was not controlled by heparin administration. However, they could measure 
heparin levels in a limited number of samples only while two different dosages were used (standard 
and intensified prophylaxis). Mean anti-Xa levels measured were low (0.35 +/- 0.20 IU/mL) and those 
levels could have been overestimated in the presence of dextran in the reagents as discussed above. It 
would thus not be unexpected to observe normal TG profiles. Of note, the reagent they used for TG 
(i.e. the PPP High Reagent®) has been designed to measure thrombin potentials in plasma samples 
containing anticoagulant drugs and therefore uses high TF concentrations to initiate TG (i.e. 20 pM 
TF). The ability of such analytical conditions to evidence a prothrombotic profile is therefore likely to 
be poor. The utilization of less intense activation seems more appropriate for this objective, but would 
require neutralization of heparin.
Third, the authors also suggested that what they refer to as ‘heparin resistance’ could be an 
explanation to the normal TG profiles observed, but they thought it not likely because AT plasma 
levels were normal, in most patients at least. However, laboratory ‘resistance’ to UFH (i.e. failure to 
achieve the therapeutic target (activated partial thromboplastin time (aPTT) or anti-Xa levels) despite 
the administration of recommended UFH doses (i.e. 400 to 600 IU/kg/day)) cannot be asserted based 
on TG, since the corresponding inhibition of TG under current, commercially available conditions 
(CAT or ST-Genesia), has not been determined, and definitely not without linking the assessment of 
heparin activity to the doses administered.[3] Furthermore, other factors besides low AT levels have 
been identified as potential causes of laboratory ‘resistance’ to heparin, such as elevated PF4 or 
heparanases. Elevated factor VIII or fibrinogen levels can also shorten the aPTT but without any 
effect on the anti-Xa assays.  Altogether, to our opinion, the observation of normal TG profiles 
despite heparin administration rather reflects the low heparin levels measured with regards to the 
hyperinflammatory state observed in most COVID-19 patients.
To illustrate differences among anti-Xa reagents and among types of heparin (UFH vs. LMWH), we 
measured in parallel anti-Xa levels with kits containing or not dextran sulfate (Biophen Heparin LRT, 
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Liquid anti-Xa, calibrated with STA-Multi Hep Calibrator, Stago Diagnostica, Asnières-sur-Seine, 
France, respectively) with a STA-R Max analyzer (Stago Diagnostica) in 28 COVID-19 plasma 
samples prospectively prepared from six COVID-19 patients admitted to the ICU (11 samples from 
patients treated with weight-adjusted UFH (Leo Pharma, Lier, Germany) and 27 samples from 
patients treated with weight-adjusted enoxaparin (Sanofi, Paris, France)). We included both peak and 
trough samples to cover a wide range of anti-Xa levels. Blood was drawn into 109mM sodium citrate 
tubes, underwent a double centrifugation (at 1500g for 15 minutes at room temperature) within one 
hour after blood collection and plasma samples were frozen at -80°C. We studied TG with the ST-
Genesia analyzer using STG-DrugScreen reagent (i.e. the reagent with the highest TF concentration 
available for the ST Genesia) according to manufacturer’s recommendations (Stago Diagnostica).[4] 
Results were normalized using a reference plasma provided with STG-DrugScreen kit of reagents and 
expressed in percentage.
We observed an overall good correlation between anti-Xa levels measured with both reagents 
(Pearson’s correlation coefficient = 0.98 for UFH samples and = 0.98 for LMWH samples). However, 
for UFH samples, the reagent containing dextran showed an overestimation of the anti-Xa levels 
compared to reagents that did not contain dextran (proportionally to anti-Xa levels; slope of the 
regression line: 1.47, 95% confidence interval: 1.24-1.71; Fig. 1A); by contrast, anti-Xa levels were 
not different between both methods for samples from patients treated with enoxaparin. These results 
further support the importance of a careful and thorough report on the methods used and of a clear 
differentiation of the anticoagulants, which frequently differently influence laboratory tests. 
A decreased thrombin potential was evidenced in relation with enoxaparin levels as assessed with 
anti-Xa assays (Fig. 1B). With more effective LMWH levels, thrombin generation was proportionally 
reduced. This suggests that that the normal TG profiles identified by the authors could first be the 
consequence of the low heparin levels measured, either as a consequence of the uncontrolled timing 
of blood collection with regards to LMWH administration (trough samples) or because heparin doses 
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Fourth, to what extent viscoelastometric tests (VETs) are truly “global” can be challenged. 
Viscoelastometric tests are attractive because they are performed with whole blood and address not 
only the platelet-dependent coagulation process, but also clot mechanical properties and at 
fibrinolysis. In our opinion such tests have major intrinsic limitations though, among which the 
initiation of clotting with massive TF concentrations (EXTEM reagents), the weak association with 
platelet function assays  and the fact that fibrinolysis is initiated by endogenous, blood-borne 
uninhibited plasminogen activators, which are most often so low that fibrinolysis is negligible.[5, 6] 
To account for the latter issue, the authors added exogenous tPA (of note very high concentrations, 
i.e. 625 ng/mL).[7] However, such modifications of commercial reagents still lack of clinical 
validation, and could lack sensitivity to the effect of the transient increase of tPA that could be present 
during initial stages of the disease.[8]
In addition, regarding D-dimers assays, the performance (i.e concordance with other reagents, 
analytical precision) in high values such as those observed in COVID-19 patients is highly variable, 
making comparisons of results from studies using different assays hazardous.[9] Moreover, to the best 
of our knowledge, the performance in high values of the kit used by the authors (HemosIL D-Dimer 
HS 500) has not been evaluated yet.
Finally, little information was provided regarding the preanalytical step of laboratory tests. For 
example, the timing of blood collection and centrifugation conditions were not specified, while these 
variables may have important influence on the tests.[10]
In order to cope efficiently with hemostatic disturbances related to COVID-19, authors of such studies 
should be urged to fully report on the laboratory methods used and to acknowledge and to 
comprehensively discuss their potential drawbacks. This is essential to enhance the interpretability 
and the applicability of the results. Studies should also be appropriately designed with regards to their 
objectives, otherwise they are at the risk of not being able to make robust conclusions. Therefore it is 
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Figure
Figure 1: Correlation between anti-Xa levels as measured with two different chromogenic anti-
Xa assays and the endogenous thrombin potential (ETP) in plasma samples from patients 
treated with heparin. Panel A represents the correlation between the two chromogenic anti-Xa 
assays depending on the type of heparin in the sample. The Biophen Heparin LRT overestimates the 
anti-Xa level of UFH samples compared to the STA-Liquid anti-Xa. Panel B represents the 
correlation between the anti-Xa levels in LMWH samples and the ETP. A progressive inhibition of 
TG is observed as measured anti-Xa levels increase. TG was studied with the ST-Genesia device 
using the STG-DrugScreen reagent and results were normalized using a reference plasma provided 
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